

Applicants: Kiran K. Chada et al.  
Serial No.: 10/768,566  
Filed : January 29, 2004  
Page 2

**In the Claims**

Please replace the currently pending set of claims with the set of claims set forth below without prejudice under the provisions of 37 C.F.R. § 1.121:

1. (Original) A method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue, or an amount of a molecule effective to stimulate expression of the sFRP-5 peptide in the subject.
2. (Original) The method of claim 1, wherein the molecule effective to stimulate expression of the sFRP-5 peptide in the subject is a polypeptide having 90% identity to SEQ ID NO. 1.
3. (Original) The method of claim 2, wherein the polypeptide has 91% identity to SEQ ID NO. 1.
4. (Original) The method of claim 3, wherein the polypeptide has 92% identity to SEQ ID NO. 1.
5. (Original) The method of claim 4, wherein the polypeptide has 95% identity to SEQ ID NO. 1.
6. (Original) The method of claim 5, wherein the polypeptide has 99% identity to SEQ ID NO. 1.
7. (Original) The method of claim 1, wherein the method comprises administration of an sFRP-5 peptide.

Applicants: Kiran K. Chada et al.  
Serial No.: 10/768,566  
Filed : January 29, 2004  
Page 3

8. (Original) The method of claim 1, wherein the subject is human.
9. (Original) The method of claim 1, wherein the administration is parenteral, intradermal, transdermal, transmucosal, rectal, subcutaneous, or by inhalation.
- 10-16. (Cancelled)
17. (Original) A method of reducing the level of adipose tissue formation in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the level of adipose tissue formation, or an amount of a molecule effective to stimulate expression of the sFRP-5 peptide in the subject.